NCT02371018

Brief Summary

The purpose of this study is to examine the effect of nutritional supplementation during hemodialysis treatment on beat-to-beat hemodynamics and treatment efficiency in a crossover design.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

February 5, 2015

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 25, 2015

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

August 2, 2018

Status Verified

September 1, 2017

Enrollment Period

2.8 years

First QC Date

February 5, 2015

Last Update Submit

August 1, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in beat-to-beat systolic blood pressure

    Beat-to-beat blood pressure will be monitored throughout the treatment by finger plethysmography

    Duration of each treatment (approximately four hours), treatments will be one week apart for a total of three weeks

Secondary Outcomes (2)

  • Gastrointestinal symptoms during treatment by a rating scale

    Duration of each treatment (approximately four hours), treatments will be one week apart for a total of three weeks

  • Treatment efficiency measured by urea removal

    Duration of each treatment (approximately four hours), treatments will be one week apart for a total of three weeks

Study Arms (3)

Standard Hemodialysis

NO INTERVENTION

Participants will be monitored during their normal hemodialysis treatment with no intervention administered

Hemodialysis with Nutrition Supplement

EXPERIMENTAL

Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.

Dietary Supplement: Nepro

Nutrition Supplement

EXPERIMENTAL

Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.

Dietary Supplement: Nepro

Interventions

NeproDIETARY_SUPPLEMENT

Patients will be asked to consume a single 8 oz can of Nepro

Hemodialysis with Nutrition SupplementNutrition Supplement

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Receiving hemodialysis treatment three times per week, on hemodialysis for greater than three months, receive medical clearance from a Nephrologists

You may not qualify if:

  • Milk or soy allergy, more than 4 hypotensive events requiring intervention in the last two weeks, hospitalized due to hypotension in the previous week

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Illinois

Urbana, Illinois, 61801, United States

Location

Related Publications (1)

  • Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2.

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Kenneth R Wilund, PhD

    University of Illinois at Urbana-Champaign

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2015

First Posted

February 25, 2015

Study Start

February 1, 2015

Primary Completion

December 1, 2017

Study Completion

July 1, 2018

Last Updated

August 2, 2018

Record last verified: 2017-09

Locations